The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio
Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup
 
Klaus Pietzner
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Novartis; Roche
 
Els Van Nieuwenhuysen
Consulting or Advisory Role - Regeneron (Inst)
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
 
Christian Marth
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; MSD; Novartis; PharmaMar; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; MSD; Novartis; PharmaMar; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Ingrid Boere
Consulting or Advisory Role - AstraZeneca (Inst); Tesaro/GSK (Inst)
Research Funding - GlaxoSmithKline (Inst)
 
Kristina Lindemann
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD; Nykode Therapeutics
Consulting or Advisory Role - Eisai; GlaxoSmithKline
Research Funding - GlaxoSmithKline
 
Josefin Fernebro
Honoraria - AstraZeneca; GlaxoSmithKline
 
Sakari Hietanen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca; GlaxoSmithKline
 
Birute Brasiuniene
Honoraria - Lilly; Merck Serono; Novartis; Sandoz; Swiss Pharma
Consulting or Advisory Role - AstraZeneca; Ipsen; Lilly; Merck Serono; MSD; Novartis; SERVIER; Swiss Pharma
Speakers' Bureau - AstraZeneca; Ipsen; Lilly; Merck Serono; MSD; Novartis; SERVIER; Swiss Pharma
Expert Testimony - Lilly; Merck Serono; Novartis; Sandoz; Swiss Pharma
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; MSD; Novartis; Swiss Pharma
Other Relationship - ESMO; European Organisation for Research and Treatment of Cancer (EORTC); Nordic Society of Gynecological Oncology (NSGO)
 
Kirsten Pors
No Relationships to Disclose
 
Signe Gybel Frederiksen
No Relationships to Disclose
 
Ulrikke Ji Mee Willerslev
No Relationships to Disclose
 
Elena Ioana Braicu
Honoraria - AstraZeneca; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
 
Kristine Madsen
No Relationships to Disclose
 
Flora Zagouri
No Relationships to Disclose